Treatment of Attention Deficit-Hyperactivity Disorder in a Pediatric Patient with COVID-19

Yıl 2023, Cilt: 18 Sayı: 2, 141 - 144, 12.07.2023

Asiye Arıcı Gürbüz , Hatice Altun

https://doi.org/10.17517/ksutfd.1100749

Öz

It is unknown that the novel Coronavirus (COVID-19), which emerged for the first time in December 2019 and spread all over the world, have affected how
many children symptomatically or asymptomatically. The uncertainty of the treatment algorithm of pandemic factor and rapidly developing pandemic process
created a chaotic environment in whole world. Children and adolescents have been adversely affected by this chaotic environment. Studies examining
the effects of this period on the mental health of children and adolescents are scarce. It has been suggested that individuals with psychiatric disorders such as
attention deficit-hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) adapted more difficultly and were affected more negatively than other
individuals. In this study, we present a patient with ADHD and oppositional defiant disorder (ODD) who was using short-acting methylphenidate (IRISMPH)
for treatment, had no worsening or any adverse side effects and was treated carefully for COVID-19 infection. However, further studies are required
to evaluate the safety of IRIS-MPH and other psychotropic agents in patients with COVID-19.

Anahtar Kelimeler

COVID 19, Attention deficit-hyperactivity disorder, Methylphenidate, Risperidone, Treatment, Child

Destekleyen Kurum

yok

Proje Numarası

yok

Teşekkür

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi® Dear Editor, Please find enclosed our manuscript entitled “Treatment of Attention Deficit - Hyperactivity Disorder in a Pediatric Patient with COVID 19” by Arıcı Gürbüz et al., for consideration of publication in “Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi ®” as an original article.By submitting the manuscript to “Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi ®”, the authors understand that the material presented in this paper has not been published before nor has been submitted for publication to another scientific journal or being consideration for publication elsewhere. The results presented in this paper have not been published previously in whole or part. I attest that this work has been read and approved by all authors. Also, the authors understand that, subject to acceptance, they will transfer copyright to the Publisher. Yours sincerely, Specialist Asiye ARICI GÜRBÜZ Department of Child and Adolescent Psychiatry , Dr. Ekrem Tok Mental Health Diseases and Hospital, Adana, Turkey E-mail: [e-mail] Phone: [phone] Fax: [phone]

Kovid-19 Tanılı Bir Pediatrik Hastada Dikkat Eksikliği-Hiperaktivite Bozukluğu Tedavisi

Öz

2019 yılı Aralık ayında ilk kez ortaya çıkan ve tüm dünyaya yayılan yeni tip koronovirüs (Kovid-19) ile semptomatik ve/veya asemptomatik enfekte olan
çocuk ve ergenlerin sayısı tam olarak bilinmemektedir. Kısa sürede gelişen pandemi sürecinin ve pandemi etkeninin tedavi algoritmasının belirsizliği tüm
dünyada kaotik bir ortam oluşturmuştur. Çocuk ve ergenler bu kaotik ortamdan olumsuz etkilenmişlerdir. Bu dönemin çocuk ve ergenlerin ruh sağlığı üzerine
etkilerini inceleyen çalışmalar kısıtlıdır. Dikkat eksikliği hiperaktivite bozukluğu (DEHB), otizm spektrum bozukluğu (OSB) gibi psikiyatrik hastalık
öyküsü olan bireylerin diğer bireylere kıyasla daha zor uyum gösterdiği ve daha olumsuz etkilendiği ileri sürülmüştür. Burada DEHB ve karşıt olma karşıt
gelme bozukluğu (KOKGB) ve Kovid-19 hastalığı birlikteliği olan, tedavisinde kısa etkili metilfenidat (IRIS-MPH) kullanımı ile Kovid-19 kliniğinde
herhangi bir kötüleşme olmayan, herhangi bir yan etki gözlenmeyen ve başarılı bir şekilde tedavi edilen bir hasta sunulmuştur. Bununla birlikte Kovid-19
hastalarında IRIS-MPH ve diğer psikotrop ajanların güvenle kullanımını değerlendiren daha ileri çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

Kovid 19, dikkat eksikliği hiperaktivite bozukluğu, metilfenidat, risperidon, tedavi, çocuk

Proje Numarası

yok

Kaynakça

• Golberstein E, Wen H, Miller BF. Coronavirus disease 2019 (COVID-19) and mental health for children and adolescents. JAMA pediatrics. 2020;174(9):819-820.
• T.C. Sağlık Bakanlığı. COVID-19 bilgilendirme platformu. Erişim adresi (22.03. 2021): https://covid19. saglik. gov. tr/TR-66935/genelkoronavirus-tablosu. html.
• Jiehao C, Jin X, Daojiong L, Zhi Y, Lei X, Zhenghai Q et al. A Case Series of children with 2019 novel coronavirus infection: Clinical and epidemiological features. Clinical Infectious Diseases. 2020;71(6):1547-1551.
• Şeker M, Özer A, Tosun Z, Korkut C, Doğrul M. Covid-19 pandemi değerlendirme raporu. Türkiye Bilimler Akademisi. 2020.
• Parıldar H, Dikici MF. Pandemiler tarihi. Klinik Tıp Aile Hekimliği. 2020;12(1):1-8.
• Liu JJ, Bao Y, Huang X, Shi J, Mental health considerations for children quarantined because of COVID-19. The Lancet Child & Adolescent Health. 2020;4(5):347-349.
• Kılınçel Ş, Kılınçel O, Muratdağı G, Aydın A, Usta MB. Factors affecting the anxiety levels of adolescents in home‐quarantine during COVID‐19 pandemic in Turkey. Asia‐Pacific Psychiatry. 2020;13(2):e12406.
• Becker SP, Gregory AM. Editorial Perspective: Perils and promise for child and adolescent sleep and associated psychopathology during the COVID‐19 pandemic. Journal of Child Psychology and Psychiatry. 2020;61(7):757-759.
• Jefsen OH, Rohde C, Nørremark B, Østergaard SD. Editorial Perspective: COVID‐19 pandemic‐related psychopathology in children and adolescents with mental illness. Journal of child psychology and psychiatry. 2020;62(6):798-800.
• Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528.
• Zhang J, Shuai L, Yu H, Wang Z, Qiu M, Lu L et al. Acute stress, behavioural symptoms and mood states among school-age children with attention-deficit/hyperactive disorder during the COVID-19 outbreak. Asian journal of psychiatry. 2020;51:102077.
• Cortese S, Asherson P, Sonuga-Barke E, Banaschewski T, Brandeis D, Buitelaar J et al. ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines Group. The Lancet Child & Adolescent Health. 2020;4(6):412-414.
• McGrath J. ADHD and COVID-19: current roadblocks and future opportunities. Ir J Psychol Med. 2020;37(3):204-211.
• Guy W. ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs. 1976.
• Turgay A. ADHD symptoms and stimulant medication side effects screening and rating scale. West Blomfield (Michigan), Integrative Therapy Institute Publication, 1994.
• Merzon E, Manor I, Rotem A, Schneider T, Vinker S, Golan Cohen A et al. ADHD as a risk factor for infection with COVID-19. Journal of Attention Disorders. 2020;25(13):1783-1790.
• Aman MG, Bukstein OG, Gadow KD, Arnold LE, Molina BS, McNamara NK et al. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? Journal of the American Academy of Child & Adolescent Psychiatry. 2014;53(1):47-60.
• Yıldız ÖÖÇ, Ağaoğlu B, Karakaya I, Şişmanlar ŞG, Memik NÇ. Dikkat eksikligi hiperaktivite bozuklugu tanili Türk çocuklarinda OROS-metilfenidatin etkinlik ve güvenilirliginin degerlendirilmesi/Efficiency and tolerability of OROS-methylphenidate in Turkish children and adolescents with attention-deficit/hyperactivity disorder. Anadolu Psikiyatri Dergisi. 2010;11(1):44.
• Çelik GG, Tahiroglu A, Avci A. Çocuk ve ergenlerde atipik antipsikotik ılaçlarin metabolik ve endokrin yan etkileri/Metabolic and endocrine side effects of atypical antipsychotic drugs in children and adolescents. Psikiyatride Guncel Yaklasimlar. 2011;3(2):232